Aqua Partners Team
James Foley, PhD
Managing Director
Over 30 years pharmaceutical industry experience spanning R&D, corporate development and licensing. Served as Head of Business Development and Licensing of pharmaceuticals for Japan and Asia/Pacific regions at Bristol Myers Squibb, SmithKline Beecham and GlaxoSmithKline. Extensive longstanding relationships with Japanese and Korean pharmaceutical industry. Former member of Board of Directors of Sosei & Co. in Tokyo. Responsible for hundreds of millions of dollars worth of transactions in anti-infectives, inflammation, cardiovascular and cancer areas. Ph.D. in Physiology and Pharmacology from Thomas Jefferson University and BA in Biology and Chemistry from Rutgers University.
Vivian Lee
Managing Director
Over 30 years experience in life science advisory, investment and portfolio management. Has advised hundreds of companies, investment firms, universities and government agencies worldwide, frequent speaker at biotechnology investment conferences in US, Europe and Asia, served as a reviewer to the US Congressional Office of Technology Assessment in its first report on commercial biotechnology in 1983. Served as Venture Partner of Global Biomedical Partners, managing $400 million International Biomedicine Fund. Former member of Board of Directors of Innodia Inc and observer on board of Syntonix Pharmaceuticals. Previously served as analyst in the Office of New Ventures of WR Grace & Co. A.B., Biochemistry from Harvard University, conducted research in tumor immunology at Dana Farber Cancer Center and Yale University School of Medicine.
Terence Porter, PhD
Managing Director
Over 30 years experience in pharmaceutical/biotechnology industry global business development and R&D. As Vice President of Search & Evaluation in the Global Business Development and Center for External Innovation groups at Takeda Pharmaceuticals, oversaw identification, evaluation and due diligence of multiple licensing and M&A opportunities in CV-Metabolic, GI, Immunology, Respiratory and CNS. As Vice President of External Science and Technology at GSK, co-led negotiations in GSK’s $450 million acquisition of Domantis. Previously headed GSK Oncology Licensing worldwide. Core member of Takeda’s Business Development & Licensing Committee and GSK’s most senior R&D scientific review and governance committee for technology platforms and compounds up to clinical proof-of-concept. BSc (Hons) in Biochemistry and Ph.D. in Chemistry from the University of Manchester, UK.
Timothy Tankosic, MD
Managing Director
Over 30 years experience in pharmaceutical, biotechnology and financial industry strategy consulting. Founded publishing and consulting company Drug & Market Development. Served as scientific adviser for biotechnology, pharmaceutical, investment and publishing firms. Previously director of product development of a small oncology therapeutics company. Author of hundreds of business reports addressing scientific, technological, clinical and market issues. Editor of Future Oncology. A.B. from Harvard University and M.D. from University of Pittsburgh School of Medicine. Conducted CNS research at Cold Spring Harbor Laboratory for Quantitative Biology and Cornell University Medical College
.png/:/cr=t:0%25,l:0%25,w:100%25,h:100%25/rs=w:600,h:300,cg:true/fx-gs)
Klaus Ulrich Berding
European Affiliate
30 years experience in banking and consulting in the life science and technology sectors. Founded Life Science & Financing Advisory in 2003. Associated Partner of BRESLIN AG specialising in corporate finance and business development for life sciences. Co-founder and Board member of Amypopharma in Italy, a spin-off from UNIMIB. Previously co-head for Germany in the Global Industry Group at Dresdner Bank, where his investment research and corporate finance activities focused on life science and technology. As SVP in the Chemicals & Healthcare Industry Group, he was responsible for managing relationships and took an active role in building the international equity business of the bank. He participated in or led over 40 IPOs and capital market transactions and M&A mandates. Klaus holds an MBA from Ruhr-Universität Bochum, and a post-graduate exam from the DVFA.